The relationship between myocardial t2* and left ventricular volumetric and functional parameters in thalassemia major patients

Early detection of cardiac involvement in thalassemia: From bench to bedside perspective

“…However, several studies demonstrated that it is not sensitive enough for early detection of the preclinical stage of cardiac involvement in TM patients due to the typical late onset of symptoms and signs [20] . Once cardiac dysfunction is detected by an echocardiogram, the survival rate of these patients is reduced [21,22] , suggesting a late stage detection of the disease by this assessment. In addition, it has been shown that the absence of a reduced left ventricular ejection fraction (LVEF) does not exclude a significant risk of sudden potential cardiac decompensation from iron overload [23] .…”

“…Patients with mild, moderate and severe cardiac iron overload (T2* 12-20, 8-12 and less than 8 ms, respectively) had impaired LVEF in [56] (r 2 = 0.003, P = 0.04) TM/776 patients Retrospective Significant relationship between cardiac R2* and ferritin / Marsella et al [59] (r = -0.359, P < 0.0001) TM/167 patients Prospective Myocardial T2* was correlated with serum ferritin / Tanner et al [60] (r = -0.34, P < 0.001) TM/19 patients, SCD/17 patients Cross sectional Cardiac 1/T2* was correlated with ferritin level / Wood et al [61] (r 2 = 0.33, P = 0.01) TM/106 patients Prospective No significant correlation between heart T2* and serum ferritin × Anderson et al [16] TM/60 patients Prospective Serum ferritin did not correlate with cardiac iron values × Merchant et al [57] TM/20 patients Prospective No correlation between serum ferritin and cardiac T2* × Kolnagou et al [58] TM/47 patients Retrospective Cardiac T2* was not associated with the serum ferritin × Bayraktaroğlu et al [22] TM: Thalassemia major; SCD: Sickle cell disease. TM/776 patients Retrospective Significant correlation between LVEF and cardiac R2* (r = -0.327, P < 0.0001) / Marsella et al [59] TM/106 patients Prospective Significant correlation of myocardial T2* below 20 ms with LVEF (r = 0.61, P < 0.0001), LVESVi (r = 0.50, P < 0.0001), and LV mass index (r = 0.40, P < 0.001) / Anderson et al [16] TM/167 patients Prospective Significant relationship between myocardial iron and LVEF (r = 0.57, P < 0.001) / Tanner et al [60] TM/67 patients Cross sectional Myocardial T2* related to LV diastolic function (EPFR, r = -0.20, P = 0.19; APFR, r = 0.49, P < 0.001; EPFR/APFR ratio, r = -0.62, P < 0.001) / Westwood et al [52] TM/33 patients Cross sectional Good correlation of DT, Tei index and E/Em index with cardiac T2* values (P < 0.05, r = 0.70-0.81) and weak correlation of E/A with T2* (P < 0.05, r = -0.44) / Barzin et al [84] TM/47 patients Retrospective Significant correlations of the myocardial T2* with LVESVi and LVEDVi (r = -0.32, P = 0.027; r = -0.29, P = 0.046, respectively) / Bayraktaroğlu et al [22] TM/19 patients, SCD/17 patients…”

“…Several studies indicated that serum ferritin was not correlated with cardiac T2* [16,22,57,58] . However, other studies with larger population size showed a weak relationship between serum ferritin and heart T2* [56,[59][60][61] .…”

Assessment of Cardiac Parameters in Evaluation of Cardiac Functions in Patients with Thalassemia Major

“…Cardiac iron accumulation (T2 * <20 ms) was shown in 87% of the patients with a LVEF of <56% among TM patients receiving conventional desferoxamine therapy [32]. In a recent study, it was reported that the patients with a T2 * value of <10 ms represented the high-risk group in terms of heart failure in the prospective follow-up of TM patients [33,34].…”

Inversion time prolongation at late enhancement cardiac magnetic resonance in a myeloma patient

“…Cardiac magnetic resonance imaging (MRI) is a reliable tool for the evaluation of cardiac function and for characterization of tissue damage in various myocardial diseases, such as cardiomyopathies (both idiopathic and associated with systemic disorders) (2,3). Cardiac MRI has also been used in oncologic patients showing signs and symptoms of cardiotoxicity (4)(5)(6)(7)(8)(9).…”